Key facts
- This page summarizes Michael H. Goldstein's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Feb 2022, 18:29.
Michael H. Goldstein - 03 Feb 2022 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)
- Reporting relationship
- President, Ophthalmology & CMO
- Issuer ticker
- OCUL
- Reported as of
- 03 Feb 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Donald Notman, Attorney-in-Fact for Michael H. Goldstein
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Michael H. Goldstein filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 07 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCUL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +63,333
- Change %
- +25%
- Price
- $0.000000
- Shares after
- 313,335
- Date
- 03 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCUL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +190,000
- Change %
- Price
- $0.000000
- Shares after
- 190,000
- Date
- 03 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 190,000
- Exercise price
- $5.27
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
Footnote F2
Includes (i) 63,333 shares of common stock of the Company underlying unvested RSUs and (ii) 2 shares of the Company's common stock acquired under the 2014 Ocular Therapuetix, Inc. Employee Stock Purchase Plan on December 31, 2021.
Footnote F3
Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
SEC remarks
Exhibit List Exhibit 24 - Power of Attorney